FuzzyBot: Importing a new version from external source

2024-03-07T09:16:04Z

Importing a new version from external source

New page

==Mechanisms of action==
===Energy intake===
* [[5-HT2C receptor|5-HT<sub>2C</sub> receptor]] agonists reduce appetite by working on [[serotonin receptor]]s in a region of the brain called the [[hypothalamus]]. [[Lorcaserin]] (Belviq) was FDA approved for weight loss but was withdrawn from the market because a safety clinical trial shows an increased occurrence of cancer.
*[[Cannabinoid receptor antagonist]]s were developed to treat obesity because researchers noticed that cannabinoid agonists (such as [[THC]], the main pharmacologically active component of [[cannabis]]), increased appetite. However, some drugs in this class such as [[rimonabant]] were withdrawn or ceased development to concerns about mental health and suicide. More selective drugs—some are in development that act only in peripheral tissues, not the brain—may be able to achieve this result with fewer adverse effects.
* [[GLP-1 agonist]]s such as tirzepatide, semaglutide, and liraglutide slow gastric emptying and also have neurologically driven effects on appetite. It is unknown if GLP-1 agonists or dual/triple agonists of GLP-1 and/or the [[glucagon receptor|glucagon]] or [[Gastric inhibitory polypeptide receptor|GIP receptors]] act solely by reducing energy intake or if they also increase energy expenditure.
*[[Setmelanotide]] is an agonist of the [[melanocortin 4 receptor]] and is used in people with certain rare genetic conditions that cause obesity. It is less effective and not approved for general obesity.
*Some weight loss drugs act on the neurotransmitters [[serotonin]], [[dopamine]], and [[norepinephrine]] to reduce appetite.

Translations:Anti-obesity medication/5/en - Revision history

FuzzyBot: Importing a new version from external source